Regulatory Rapporteur November 2025 – Contents
TOPRA Symposium 2025: Leading with impact
November 2025 – Contents: Human medicines sessions
November 2025 – Contents: Medical devices/IVD sessions
November 2025 – Contents: Veterinary medicines sessions
PS1: Tailored development of biosimilars without efficacy and safety studies – Is this the future?
PS2: Navigating the green horizon – Environmental sustainability and regulatory affairs
SME1: Regulatory updates for SMEs, academia and start-ups
- Previous
- Next
MHRA advances new reform for the treatment of rare diseases
This industry news update explores the MHRA’s upcoming framework that addresses treatments related to rare diseases.
EMA ETF offers scientific advice for antimicrobial resistance
This is an industry news update about the EMA’s ETF that offers scientific advice for antimicrobial resistance.
EMA launches #HealthNotHype campaign
This industry news update shares the EMA’s new social media campaign to raise awareness for GLP-1 medicines.
More news
MHRA cuts approval times for UK clinical trials in half
This industry news update announces the MHRA’s decision to reduce clinical trial approvals from 91 days to 41 days.
NICE reviews health technology assessment to better support patients
This industry news update shares NICE’s plans to review how health technologies are evaluated.
Regulatory Rapporteur is back in PDF format
News of an exciting new development for Regulatory Rapporteur starting in October 2025.
MHRA cross-agency team outlines emerging considerations for the manufacture of personalised medicines
This industry news update shares the MHRA’s guidance for the manufacture of personalised medicines.
RegRapPod − InConversation with Zohra Nasir and Aksa Rahman
InConversation talks careers withZohra Nasir and Aksa Rahman
- Previous
- Next
The Organisation for Professionals in Regulatory Affairs
- Contact us
- Copyright © 2015-2025 The Organisation for Professionals in Regulatory Affairs Ltd. t/a Regulatory Rapporteur - All rights reserved